H

Halozyme Therapeutics
D

HALO

57.750
USD
0.32
(0.56%)
Market Closed
Volume
40,211
EPS
5
Div Yield
-
P/E
17
Market Cap
7,112,085,750
Related Instruments
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    X
    XENE
    0.410
    (1.04%)
    39.690 USD
    More
News

Title: Halozyme Therapeutics

Sector: Healthcare
Industry: Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.